PROMIS – PRospective study Of MammaPrint in breast cancer patients with an Intermediate recurrence Score

Publication Name: Cancer Research

Author(s): Hatem Soliman, Sarah Untch, Lisette Stork-Sloots

PROMIS is a prospective study that will investigate the additional value of MammaPrint, BluePrint and TargetPrint in women with an intermediate Oncotype DX score. An initial CRF – capturing baseline patient characteristics, pathology information, Oncotype DX score and the recommended treatment plan – will be completed before receiving the MammaPrint result. A second CRF – capturing the actual treatment – will be completed within 4 weeks after receiving the MammaPrint result. See article.